Insys Therapeutics (INSY) Reaches $12.41 After 4.00% Up Move; Materion (MTRN) Covered By 0 Bulls

July 17, 2017 - By Vivian Park

Among 3 analysts covering Materion (NYSE:MTRN), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Materion had 6 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was initiated by Wm Smith on Thursday, November 3 with “Not Rated”. The company was maintained on Friday, July 7 by Jefferies. Jefferies maintained the stock with “Hold” rating in Friday, June 2 report. Stifel Nicolaus upgraded the shares of MTRN in report on Thursday, August 27 to “Hold” rating. The company was downgraded on Thursday, April 7 by Stifel Nicolaus. The stock has “Hold” rating by Jefferies on Wednesday, January 13. See Materion Corp (NYSE:MTRN) latest ratings:

07/07/2017 Broker: Jefferies Rating: Hold New Target: $34.0000 Maintain
02/06/2017 Broker: Jefferies Rating: Hold New Target: $34.0000 Maintain

The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 327,277 shares traded. Insys Therapeutics Inc (NASDAQ:INSY) has declined 5.69% since July 17, 2016 and is downtrending. It has underperformed by 22.39% the S&P500.The move comes after 5 months positive chart setup for the $850.29 million company. It was reported on Jul, 17 by Barchart.com. We have $12.91 PT which if reached, will make NASDAQ:INSY worth $34.01 million more.

Since May 16, 2017, it had 4 insider buys, and 0 selling transactions for $268,142 activity. Shares for $53,932 were bought by Motahari Saeed on Tuesday, May 16. The insider Vishnoi Rohit bought $56,575. Shares for $97,680 were bought by MEYER STEVEN J.

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The company has market cap of $850.29 million. The Firm develops and commercializes supportive care products. It currently has negative earnings. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Investors sentiment decreased to 0.86 in 2016 Q4. Its down 0.37, from 1.23 in 2016Q3. It dived, as 21 investors sold Insys Therapeutics Inc shares while 43 reduced holdings. 21 funds opened positions while 34 raised stakes. 27.44 million shares or 9.45% less from 30.31 million shares in 2016Q3 were reported. Rhumbline Advisers has 28,744 shares for 0% of their portfolio. Paloma Prns Com reported 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Parametric Portfolio Assoc Ltd owns 19,112 shares. Gotham Asset Ltd Liability Corp has invested 0.02% in Insys Therapeutics Inc (NASDAQ:INSY). Goldman Sachs Gru Incorporated accumulated 0% or 265,736 shares. Van Eck Associate Corp invested in 866 shares or 0% of the stock. Deutsche Fincl Bank Ag stated it has 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Private Ocean Llc stated it has 130 shares or 0% of all its holdings. Moreover, Wealthtrust has 0% invested in Insys Therapeutics Inc (NASDAQ:INSY) for 200 shares. The Switzerland-based Swiss Bank has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Ny State Common Retirement Fund, a New York-based fund reported 22,700 shares. 1,359 were reported by Panagora Asset Mngmt. New York-based Amer Group Incorporated Inc has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Credit Agricole S A invested 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Jw Asset Management Limited Liability Corporation reported 29,409 shares stake.

Among 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insys Therapeutics had 12 analyst reports since August 4, 2015 according to SRatingsIntel. On Thursday, September 22 the stock rating was maintained by RBC Capital Markets with “Outperform”. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, December 21 report. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, June 1 report. On Thursday, August 4 the stock rating was maintained by Jefferies with “Buy”. On Monday, October 10 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Buy” rating on Thursday, April 14 by Janney Capital. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Wednesday, February 24 by Jefferies. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Friday, June 9 by Jefferies. The stock has “Buy” rating by Zacks on Friday, August 14. JMP Securities maintained the shares of INSY in report on Wednesday, March 9 with “Market Outperform” rating.

Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on August, 2. They expect $-0.10 earnings per share, down 266.67% or $0.16 from last year’s $0.06 per share. After $-0.09 actual earnings per share reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

Investors sentiment decreased to 0.95 in 2016 Q4. Its down 0.35, from 1.3 in 2016Q3. It dived, as 11 investors sold Materion Corp shares while 54 reduced holdings. 19 funds opened positions while 43 raised stakes. 17.55 million shares or 0.88% less from 17.71 million shares in 2016Q3 were reported. Credit Suisse Ag has 25,209 shares for 0% of their portfolio. Meyer Handelman holds 11,500 shares. Menta Capital Ltd Limited Liability Company holds 0.17% or 51,161 shares in its portfolio. Gsa Capital Prns Limited Liability Partnership has 8,100 shares for 0.02% of their portfolio. Mason Street Advsr Limited Liability Company has invested 0% in Materion Corp (NYSE:MTRN). Peak6 Investments Limited Partnership stated it has 800 shares. New Jersey-based Jacobs Levy Equity Mngmt has invested 0.04% in Materion Corp (NYSE:MTRN). Walthausen And Commerce Ltd has 296,845 shares for 1.09% of their portfolio. Westpac holds 8,322 shares. Louisiana State Employees Retirement Systems invested in 0.02% or 8,000 shares. Trust Of Vermont owns 200 shares. Oppenheimer & stated it has 37,250 shares or 0.04% of all its holdings. Heartland reported 231,802 shares. Keybank National Association Oh reported 9,844 shares stake. 1.68M are held by Dimensional Fund Lp.

Since March 16, 2017, it had 0 buys, and 22 sales for $3.02 million activity. $184,000 worth of Materion Corp (NYSE:MTRN) was sold by Hipple Richard J.

Materion Corporation, through its subsidiaries, is an integrated producer of engineered materials used in a range of electrical, electronic, thermal, and structural applications. The company has market cap of $759.20 million. The Firm operates in four divisions: Performance Alloys and Composites, Advanced Materials, Precision Coatings, and Other. It has a 32.78 P/E ratio. The Performance Alloys and Composites segment consists of businesses, such as Performance Metals and Technical Materials.

About 44,408 shares traded. Materion Corp (NYSE:MTRN) has risen 47.97% since July 17, 2016 and is uptrending. It has outperformed by 31.27% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: